S&P 500   4,443.11
DOW   34,869.37
QQQ   370.35
pixel
pixel
pixel
S&P 500   4,443.11
DOW   34,869.37
QQQ   370.35
pixel
pixel
pixel
S&P 500   4,443.11
DOW   34,869.37
QQQ   370.35
pixel
pixel
pixel
S&P 500   4,443.11
DOW   34,869.37
QQQ   370.35
pixel
pixel
pixel
NYSE:NVTA

Invitae Stock Forecast, Price & News

$30.08
+0.02 (+0.07 %)
(As of 09/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$28.71
$30.28
50-Day Range
$24.31
$32.19
52-Week Range
$24.16
$61.59
Volume2.27 million shs
Average Volume3.84 million shs
Market Capitalization$6.54 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.84
30 days | 90 days | 365 days | Advanced Chart
Receive NVTA News and Ratings via Email

Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter.


Invitae logo

About Invitae

Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Employees
2,100
Year Founded
N/A

Sales & Book Value

Annual Sales
$279.60 million
Book Value
$10.63 per share

Profitability

Net Income
$-602,170,000.00
Net Margins
-149.68%

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$6.54 billion
Next Earnings Date
11/4/2021 (Estimated)
Optionable
Optionable

MarketRank

Overall MarketRank

2.16 out of 5 stars

Medical Sector

383rd out of 1,353 stocks

Medical Laboratories Industry

11th out of 30 stocks

Analyst Opinion: 3.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












Invitae (NYSE:NVTA) Frequently Asked Questions

Is Invitae a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Invitae stock.
View analyst ratings for Invitae
or view top-rated stocks.

What stocks does MarketBeat like better than Invitae?

Wall Street analysts have given Invitae a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Invitae wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Invitae's next earnings date?

Invitae is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Invitae
.

How were Invitae's earnings last quarter?

Invitae Co. (NYSE:NVTA) released its earnings results on Tuesday, August, 3rd. The medical research company reported ($0.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.65) by $0.20. The medical research company had revenue of $116.31 million for the quarter, compared to analyst estimates of $109.53 million. Invitae had a negative trailing twelve-month return on equity of 26.29% and a negative net margin of 149.68%.
View Invitae's earnings history
.

How has Invitae's stock been impacted by Coronavirus?

Invitae's stock was trading at $15.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NVTA shares have increased by 89.8% and is now trading at $30.08.
View which stocks have been most impacted by COVID-19
.

What guidance has Invitae issued on next quarter's earnings?

Invitae issued an update on its FY 2021 earnings guidance on Tuesday, August, 24th. The company provided EPS guidance of for the period. The company issued revenue guidance of $475 million-$500 million, compared to the consensus revenue estimate of $463.25 million.

What price target have analysts set for NVTA?

9 analysts have issued 1-year price targets for Invitae's stock. Their forecasts range from $33.00 to $58.00. On average, they anticipate Invitae's stock price to reach $42.33 in the next twelve months. This suggests a possible upside of 40.7% from the stock's current price.
View analysts' price targets for Invitae
or view top-rated stocks among Wall Street analysts.

Who are Invitae's key executives?

Invitae's management team includes the following people:
  • Sean Emerson George, Chairman, President & Chief Executive Officer
  • Kenneth D. Knight, Chief Operating Officer
  • Roxi Wen, Chief Financial Officer
  • Robert Nussbaum, Chief Medical Officer
  • Layton Wedgeworth, Chief Technology Officer

What is Sean George's approval rating as Invitae's CEO?

59 employees have rated Invitae CEO Sean George on Glassdoor.com. Sean George has an approval rating of 87% among Invitae's employees.

What other stocks do shareholders of Invitae own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Square (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), The Trade Desk (TTD), Shopify (SHOP), salesforce.com (CRM), Advanced Micro Devices (AMD) and Okta (OKTA).

When did Invitae IPO?

(NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

What is Invitae's stock symbol?

Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Who are Invitae's major shareholders?

Invitae's stock is owned by a number of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (10.71%), Vanguard Group Inc. (7.96%), Sumitomo Mitsui Trust Holdings Inc. (7.45%), Nikko Asset Management Americas Inc. (7.44%), Macquarie Group Ltd. (2.78%) and Perceptive Advisors LLC (2.22%). Company insiders that own Invitae stock include Artur Bergman, E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert L Nussbaum, Sean E George, Sean E George, Shelly D Guyer and Thomas Brida.
View institutional ownership trends for Invitae
.

Which institutional investors are selling Invitae stock?

NVTA stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Perceptive Advisors LLC, Perceptive Advisors LLC, Citadel Advisors LLC, Wells Fargo & Company MN, Compagnie Lombard Odier SCmA, Redmile Group LLC, and Ikarian Capital LLC. Company insiders that have sold Invitae company stock in the last year include Artur Bergman, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert L Nussbaum, Sean E George, Shelly D Guyer, and Thomas Brida.
View insider buying and selling activity for Invitae
or view top insider-selling stocks.

Which institutional investors are buying Invitae stock?

NVTA stock was acquired by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Light Street Capital Management LLC, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Goldman Sachs Group Inc., Geode Capital Management LLC, Alyeska Investment Group L.P., and Northern Trust Corp.
View insider buying and selling activity for Invitae
or or view top insider-buying stocks.

How do I buy shares of Invitae?

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Invitae's stock price today?

One share of NVTA stock can currently be purchased for approximately $30.08.

How much money does Invitae make?

Invitae has a market capitalization of $6.54 billion and generates $279.60 million in revenue each year. The medical research company earns $-602,170,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis.

How many employees does Invitae have?

Invitae employs 2,100 workers across the globe.

What is Invitae's official website?

The official website for Invitae is www.invitae.com.

Where are Invitae's headquarters?

Invitae is headquartered at 1400 16th Street, SAN FRANCISCO CA, 94103.

How can I contact Invitae?

Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at (415) 374-7782 or via email at [email protected].


This page was last updated on 9/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.